Healthcare AI Is Now About Dollars, Not Dazzle
Hospitals running on thin margins are done chasing clinical moonshots. This year, healthcare AI spend hit $1.4 billion-nearly triple 2024-with health systems driving 75% of it to cut costs and curb burnout. Predictive AI embedded in EHRs climbed to 71% adoption in 2024, with billing automation and revenue cycle tools growing fastest. With roughly 40% of hospitals operating in the red, the bar is simple: buy what pays for itself.
Five companies are leaning into this "economic validation" trend: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Butterfly Network (NYSE: BFLY), Hims & Hers Health (NYSE: HIMS), Clover Health (NASDAQ: CLOV), and iRhythm Technologies (NASDAQ: IRTC). The market is projected to reach $110.61 billion by 2030, growing at a 38.6% clip from 2025 as ROI-focused tools replace pilots that never left the sandbox.
- Hospital margins remain under pressure, intensifying demand for cost-saving tech.
- Burnout is still a capacity threat, so automation that gives time back gets fast-track attention.
VentriPoint Diagnostics: CFO Appointment Signals a Scale Mindset
VentriPoint Diagnostics named David Swetlow as CFO to help scale its VMS+ cardiac imaging platform. Leadership framed the move as a push to tighten commercial execution, expand globally, and drive revenue growth. Swetlow brings 25+ years in medtech and life sciences across finance, capital markets, and commercialization (Sernova, Ondine, Protox, HealthPricer, One Person Health, QLT, Xillix).
The company's recent steps focus squarely on value and velocity. VMS+ creates 3D heart models from standard 2D echo images, with previously published data showing agreement with MRI. A collaboration with Providence Health Care Ventures will validate whether AI-enhanced echo can reduce demand for cardiac MRI at St. Paul's Hospital in Vancouver, with implementation targeted for early 2026.
Commercially, VentriPoint is moving to a Device-as-a-Service subscription to shorten sales cycles and build recurring revenue. The company reported growing qualified leads in North America and Europe, a renewed commitment and investment from European distributor AngioPro, and successful quality audits with zero major nonconformities. VMS+ maintains FDA clearance, Health Canada licensing, and EU MDR certification.
Butterfly Network: Turning POCUS Into Billable Throughput
Butterfly launched Compass AI, an enterprise platform to turn point-of-care ultrasound from an underused tool into a compliant, billable service line. By tackling undocumented exams-estimated at 85% in many settings-the company says health systems can capture up to 5x more revenue from existing volume.
Key features include a Documentation Agent that uses ambient voice input to cut charting time by up to 25%, plus a QA Agent with AI feedback to speed image review. The platform spans departments and devices, providing real-time visibility into usage, credentialing, and quality metrics.
Hims & Hers Health: Labs Makes Biomarkers Routine
Hims & Hers rolled out Labs, a biomarker testing platform that tracks key markers over time and provides doctor-developed action plans. The Base plan is $199/year (50 biomarkers across 9 categories); the Advanced plan is $499/year (120+ biomarkers across 10 categories).
The roadmap includes at-home devices, new biomarker panels (e.g., bone and brain health), and advanced diagnostics for chronic conditions. For health operators, this signals ongoing consumer pull for convenient, longitudinal testing and guidance.
Clover Health: AI Support for Earlier Detection and Fewer Admissions
Counterpart Health, a Clover subsidiary, reported that physicians using its Counterpart Assistant saw meaningfully higher diagnosis rates versus controls: diabetes (+75%), chronic kidney disease (+89%), and chronic heart failure (+89%). The platform was also associated with lower acute care use, including 7.6%-21.2% reductions in all-cause inpatient hospitalizations.
The message for primary care networks is clear: decision support embedded in workflow can move upstream on chronic disease and reduce avoidable admissions-especially in underserved populations.
iRhythm Technologies: Zio Consistency Across Populations
iRhythm shared data on more than 408,000 U.S. patients showing its Zio system delivered comparable wear time and atrial fibrillation detection across Asian and non-Asian groups. The analysis supports consistent performance and generalizability of 14-day continuous monitoring.
Japan is the second-largest ambulatory cardiac monitoring market (~1.6M tests annually). iRhythm is active there via exclusive distributor Senko Medical Instrument, with a deep-learned AI algorithm approved by Japan's PMDA.
What Healthcare Leaders Should Do Next
- Prioritize use cases that print a P&L: billing capture, RCM, imaging throughput, and capacity relief.
- Demand time-to-value: 90-day go-live targets, prebuilt EHR hooks, and minimal workflow friction.
- Ask for quantified proof: baseline vs. post metrics on revenue capture, denial rates, charting minutes saved, and MRI/CT diversion.
- Model TCO and pricing: subscription terms, per-exam pricing, and service-level guarantees tied to financial outcomes.
- Verify quality and compliance: audit history, credentialing workflows, and documentation coverage rates.
- Plan change management: training, clinical champions, QA cadence, and weekly executive dashboards.
- Start where data is cleanest: echo, ambulatory ECG, and RCM tend to be fastest to operationalize.
Bottom Line
AI that fixes documentation, recovers revenue, and trims avoidable imaging or admissions is getting greenlit. The next winners will be the teams that prove financial lift early, integrate cleanly with EHRs, and scale across sites without adding admin drag.
If your team is building internal skills for practical AI in operations, see curated options by role at Complete AI Training.
Your membership also unlocks:
